Inicio Actualidad

The Big Society and Public Service Reform

Cameron's Big Society and private initiative.

Upcoming review of the EU Data Protection Directive: How will it affect Your business?

The revision of the EU Data Protection Directive is to bring up to date the European laws dating back to 1995. This is to affect many businesses on Telecommunications, Advertising, Car Manufacturing, Pharmaceutical, Travel and Tourism sectors which will have to pay attention to this new directive and be ready for the forthcoming changes.

Proyecto de Ley de Dinero Electrónico

Desde conchas, sal o monedas de oro a billetes…el dinero ha revestido múltiples formas y su valor se ha regido por diferentes sistemas. Hoy sin embargo, como no puede ser de otra manera, una parte cada vez más importante del dinero que manejamos es electrónico.


Nace POLITICAS, el hub de referencia en lobby y Public Affairs.

Calidad del Aire: Nueva legislación y oportunidades para las empresas

La aprobación del Real Decreto 102/2011, de 28 de enero, relativo a la mejora de la calidad del aire incluye disposiciones sobre la gestión y evaluación de la calidad del aire que supone, entre otras cosas, una importante oportunidad para las empresas del sector.

How could the current discussions on e-Commerce impact Internet Service Providers liability?

The European Commission launched in August a questionnaire on the e-commerce Directive, which re-opens the discussions on the liability of the Internet Service Providers when dealing with illegal contents. This consultation could lead to a future update of the e-Commerce Directive and the protection regime accorded to Internet providers in the European Union.

How pharma will have to deal with the renewed NHS in England

The Conservative-Liberal Democrat coalition released a White Paper in July, setting out proposals for the future direction of the Health Service (NHS). It will bring large-scale structural changes to the NHS as well as a renewed focus on patient outcomes and patient choice. The changes are intended to make the healthcare system more clinically led, with decision making devolved to the ‘front line’ (GPs) rather than with managers. Although the Pharmaceutical Industry has broadly welcomed these proposals, it clearly needs to start to engage more with this potential key-actors and should already be seeking relationships with those ‘thought leading’ GPs who may end up leading the GP consortia.

Inteligencia de Political Intelligence

Resumen Semanal